biostudies-literatureHaroun-Izquierdo ANCI NIH HHSe005577https://www.ebi.ac.uk/biostudies/studies/S-EPMC9628692biostudies-literatureUnknown10(11)<h4>Background</h4>Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)⁺NKG2C⁺ adaptive NK cells to maximize missing-self reactivity.<h4>Methods</h4>We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry Journal for immunotherapy of cancerAdaptive single-KIR⁺NKG2C⁺ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia.PMC9628692P01 CA111412Miller JSBlomberg PSohlberg EKrokeide SZBerggren SValamehr BOnfelt BKremer VLjunggren HGHammer QBendzick LBjorklund AZhang BWikstrom KFelices MMomayyezi Pvan Ooijen HKanaya MTjonnfjord GKveberg LLi SVincenti MCichocki FWiiger MTHaroun-Izquierdo ANetskar HHoglund PMalmberg KJHoel HJAlici EfalseAdaptive single-KIR⁺NKG2C⁺ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia.<h4>Background</h4>Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)⁺NKG2C⁺ adaptive NK cells to maximize missing-self reactivity.<h4>Methods</h4>We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry 2022-01-01T00:00:00Z2022 Nov2026-07-16T18:34:17.271Z2026-07-11T03:08:39.349ZS-EPMC96286923631906510.1136/jitc-2022-005577